/NVCN
NVCN Stock - Neovasc Inc.
Healthcare|Medical - DevicesNASDAQ
$30.03+0.00%
+$0.00 (+0.00%) • Apr 10
64
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.85
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.39
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $33.03
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for NVCN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$29.73 – $30.33
TARGET (TP)$34.53
STOP LOSS$27.63
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.01
52W High$30.07
52W Low$4.58
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | $3.81M | $2.55M | $1.96M | $2.09M | $1.75M |
| Gross Profit | $3.03M | $1.99M | $1.51M | $1.63M | $1.38M |
| Gross Margin | 79.7% | 78.2% | 77.2% | 78.1% | 79.1% |
| Operating Income | $-33,740,809 | $-31,109,541 | $-34,883,699 | $-29,939,859 | $-31,168,604 |
| Net Income | $-41,204,418 | $-24,889,069 | $-28,695,041 | $-35,131,015 | $-108,042,868 |
| Net Margin | -1082.9% | -977.0% | -1466.0% | -1679.3% | -6176.9% |
| EPS | $-15.07 | $-9.88 | $-43.04 | $-134.88 | $-1907.54 |
Company Overview
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
NVCNBeat Rate
38%
Last 13 quarters
Avg Surprise
-39.6%
EPS vs Estimate
Beats / Misses
5/8
Last 12 quarters
Latest EPS
$-5.03
Q1 2023
EPS Surprise History
Q3 21
-44.4%
$-3.25vs$-2.25
Q4 21
+8.3%
$-2.75vs$-3.00
Q4 21
No data
Q2 22
-200.0%
$-3.75vs$-1.25
Q3 22
-82.8%
$-3.29vs$-1.80
Q4 22
-6.4%
$-3.00vs$-2.82
Q4 22
No data
Q1 23
-85.6%
$-5.03vs$-2.71
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2024 | Mar 29, 2024 | — | — | — | — |
Q4 2023 | Nov 8, 2023 | — | — | — | — |
Q3 2023 | Aug 9, 2023 | $-2.71 | — | — | — |
Q1 2023 | Mar 31, 2023 | $-2.71 | $-5.03 | -85.6% | ✗ MISS |
Q4 2022 | Dec 31, 2022 | — | $-5.06 | — | — |
Q4 2022 | Nov 10, 2022 | $-2.82 | $-3.00 | -6.4% | ✗ MISS |
Q3 2022 | Aug 11, 2022 | $-1.80 | $-3.29 | -82.8% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-1.25 | $-3.75 | -200.0% | ✗ MISS |
Q4 2021 | Dec 31, 2021 | — | $-2.47 | — | — |
Q4 2021 | Nov 9, 2021 | $-3.00 | $-2.75 | +8.3% | ✓ BEAT |
Q3 2021 | Aug 10, 2021 | $-2.25 | $-3.25 | -44.4% | ✗ MISS |
Q2 2021 | May 6, 2021 | $-2.37 | $-1.00 | +57.8% | ✓ BEAT |
Q4 2020 | Dec 31, 2020 | — | $-10.76 | — | — |
Q4 2020 | Nov 5, 2020 | $-11.33 | $-12.75 | -12.5% | ✗ MISS |
Q3 2020 | Aug 6, 2020 | $-13.58 | $-20.25 | -49.1% | ✗ MISS |
Q2 2020 | May 7, 2020 | $-13.75 | $-9.50 | +30.9% | ✓ BEAT |
Q4 2019 | Dec 31, 2019 | — | $-33.72 | — | — |
Q4 2019 | Nov 7, 2019 | $-27.75 | $-20.75 | +25.2% | ✓ BEAT |
Q3 2019 | Aug 7, 2019 | $-30.00 | $-29.25 | +2.5% | ✓ BEAT |
Q2 2019 | May 9, 2019 | $-18.33 | $-47.50 | -159.1% | ✗ MISS |
Latest News
Loading news...
Frequently Asked Questions about NVCN
What is NVCN's current stock price?
Neovasc Inc. (NVCN) is currently trading at $30.03 per share. The stock has moved +0.00% today.
What is the analyst price target for NVCN?
No analyst price targets are currently available for this stock.
What sector is Neovasc Inc. in?
Neovasc Inc. operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the NASDAQ exchange.
What is NVCN's market cap?
Neovasc Inc. has a market capitalization of $0.08 billion, making it a small-cap company.
Does NVCN pay dividends?
No, Neovasc Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorASXC
Asensus Surgical, Inc.
$0.35
Mkt Cap: $0.1B
BLI
Berkeley Lights, Inc.
$1.20
Mkt Cap: $0.1B
IGMS
IGM Biosciences, Inc.
$1.27
Mkt Cap: $0.1B
IMDX
Insight Molecular Diagnostics Inc.
$5.41
Mkt Cap: $0.2B
JBIO
Jade Biosciences, Inc.
$17.03
Mkt Cap: $0.6B
LFWD
Lifeward Ltd.
$0.65
Mkt Cap: $0.0B
NVNO
enVVeno Medical Corporation
$0.32
Mkt Cap: $0.0B
ZOM
Zomedica Corp.
$0.10
Mkt Cap: $0.1B
ZYNE
Zynerba Pharmaceuticals, Inc.
$1.30
Mkt Cap: $0.1B
Explore stocks similar to NVCN for comparison